| Antiretroviral Therapy | Category | Clarifications/Special considerations |
|---|---|---|
| a) Nucleoside reverse transcriptase inhibitors (NRTIs) | Clarification: Antiretroviral drugs have the potential to either decrease or increase the levels of steroid hormones in women using hormonal contraceptives. Read More |
|
| Abacavir (ABC) | 1 | |
| Tenofovir (TDF) | 1 | |
| Zidovudine (AZT) | 1 | |
| Lamivudine (3TC) | 1 | |
| Didanosine (DDI) | 1 | |
| Emtricitabine (FTC) | 1 | |
| Stavudine (D4T) | 1 | |
| b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | ||
| Efavirenz (EFV) | ||
| Etravirine (ETR) | DMPA=1 NET-EN=2 |
|
| Nevirapine (NVP) | 1 | |
| Rilpivirine (RPV) | DMPA=1 NET-EN=2 |
|
| c) Protease inhibitors (PIs) | ||
| Ritonavir-boosted atazanavir (ATV/r) | ||
| Ritonavir-boosted lopinavir (LPV/r) | DMPA=1 NET-EN=2 |
|
| Ritonavir-boosted darunavir (DRV/r) | DMPA=1 NET-EN=2 |
|
| Ritonavir (RTV) | DMPA=1 NET-EN=2 |
|
| d) Integrase inhibitors | ||
| Raltegravir (RAL) | DMPA=1 NET-EN=2 |